Resources from the same session
LBA2 - Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study
Presenter: Mark Awad
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
194MO - Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results
Presenter: Yan Zhang
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA2 and 194MO
Presenter: Gerard Hanna
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
1MO - A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation
Presenter: yongchang zhang
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
137MO - Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)
Presenter: Zhang Li
Session: Mini Oral session 1
Resources:
Abstract
2MO - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON
Presenter: Enriqueta Felip
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast